Central nervous system international prognostic index impacts overall survival in diffuse large b-cell lymphoma treated with r-chop in a third level cancer center from Mexico: a survey of 642 patients
Rev. invest. clín
;
73(4): 231-237, Jul.-Aug. 2021. tab, graf
Article
in English
| LILACS
| ID: biblio-1347569
ABSTRACT
Background:
Central nervous system international prognosis index (CNS-IPI) is validated in European and the USA cancer databases. However, no validation has been done in Mexican population.Objective:
The objective of the study was to assess the impact of the CNS-IPI on central nervous system (CNS) relapse and survival in Mexican patients with diffuse large B-cell lymphoma (DLBCL).Methods:
In this retrospective analysis, clinical, biochemical, and histological variables and the CNS-IPI were analyzed.Results:
Six hundred and forty-two patients with DBLCL were included in the study. The mean ± SD age was 56.8 ± 14.9 years. Most had an ECOG of 0-1 75% (n = 484) had absence of B-symptoms and advanced disease (clinical stage III-IV, n = 433, 67.4%). According to the CNS-IPI, almost one-half were in the low-risk category. According to the CNS-IPI, CNS relapse rate was 1.36% (95% CI 83.2-92.8), 3.1% (95% CI 132.4-162.8), and 7.4% (95% CI 61-91) for patients in the low-, intermediate-, and high-risk categories, respectively. The median overall survival in the high-risk group (CNS-IPI) was 22 months, and it has not been achieved after 80 months of follow-up for the other groups.Conclusions:
CNS-IPI was associated with survival; therefore, we propose its use as a prognostic tool for prospective validation.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Antineoplastic Combined Chemotherapy Protocols
/
Lymphoma, Large B-Cell, Diffuse
/
Central Nervous System Neoplasms
Type of study:
Observational study
/
Prognostic study
/
Risk factors
Limits:
Adult
/
Aged
/
Humans
Country/Region as subject:
Mexico
Language:
English
Journal:
Rev. invest. clín
Journal subject:
Medicine
Year:
2021
Type:
Article
Affiliation country:
Mexico
Institution/Affiliation country:
Instituto Nacional de Cancerología/MX
Similar
MEDLINE
...
LILACS
LIS